Subscribe To Our Free Newsletter |
Dr Reddy’s Labs shares up 3% after Q2 results. What should investors do?
Dr. Reddy's Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While analysts acknowledge the strong revenue momentum, opinions are divided on the stock's future prospects, with ratings ranging from 'Buy' to 'Sell'.